Contents

Preface vii
Contributors to Volume 1 ix
Contents of All Volumes xi

Historical Perspective

1.1 Medicinal Chemistry: A Personal View
A. BURGER, University of Virginia, Charlottesville, VA, USA 1

1.2 Chronology of Drug Introductions
W. SNEADER, University of Strathclyde, Glasgow, UK 7

1.3 Evolution of the Pharmaceutical Industry
J. LIEBENAU, London School of Economics, UK 81

1.4 Development of Medicinal Chemistry in China
HUANG LIANG and ZHOU JIN, Chinese Academy of Medical Sciences, Beijing, People's Republic of China 99

1.5 Contribution of Ayurvedic Medicine to Medicinal Chemistry
N. ANAND, Central Drug Research Institute, Lucknow, India 113

Targets of Biologically Active Molecules

2.1 Physiology of the Human Body
J. R. McCLINTIC, California State University, Fresno, CA, USA 133

2.2 The Architecture of the Cell
P. D. KENNEWELL, Roussel Laboratories Ltd, Swindon, UK 169

2.3 Macromolecular Targets for Drug Action
T. P. KENAKIN, Glaxo Research Laboratories, Research Triangle Park, NC, USA 195

2.4 The Concept of Bioselectivity
T. P. KENAKIN, Glaxo Research Laboratories, Research Triangle Park, NC, USA 209

2.5 The Immune System

2.6 Selectivity
R. L. LIPNICK, Environmental Protection Agency, Washington, DC, USA 239

Bioactive Materials

3.1 Classification of Drugs
A. BURGER, University of Virginia, Charlottesville, VA, USA 249

3.2 Lead Structure Discovery and Development
G. DESTEVENES, Drew University, Madison, NJ, USA 261

3.3 Computer-aided Selection for Large-scale Screening
L. HODES, National Cancer Institute, Bethesda, MD, USA 279

3.4 Isolation of Bioactive Materials and Assay Methods
W. R. BUTT, Birmingham & Midland Hospital for Women, UK 285

3.5 Biomaterials from Mammalian Sources
W. R. BUTT, Birmingham & Midland Hospital for Women, UK 303

3.6 Development and Scale-up of Processes for the Manufacture of New Pharmaceuticals
T. LAIRD, Smith Kline & French Research Ltd, Tonbridge, UK 321
3.7 Genetic Engineering: The Gene
K. DRLICA, Public Health Research Institute, New York, NY, USA

3.8 Genetic Engineering: Applications to Biological Research
S. P. ADAMS, Monsanto Company, St Louis, MO, USA

3.9 Genetic Engineering: Commercial Applications
P. BOST and G. BOURAT, Rhône-Poulenc Santé, Antony, France and
A.-C. JOUANNEAU, Genex International, Paris, France

Socio-economic Factors of Drug Development

4.1 Industrial Factors and Government Controls
G. E. POWDERHAM, Roussel Laboratories Ltd, Uxbridge, UK

4.2 Organization and Funding of Medical Research in the UK
N. E. J. WELLS, Office of Health Economics, London, UK

4.3 Organization and Funding of Medical Research in the USA
P. S. CALLERY, University of Maryland, Baltimore, MD, USA

4.4 Health Care in the UK
D. TAYLOR, ABPI, London, UK

4.5 Health Care in the USA
J. E. FINCHAM, Samford University, Birmingham, AL, USA

4.6 Good Pharmaceutical Manufacturing Practice
J. SHARP, Waverley Pharmaceutical Ltd, Runcorn, UK

4.7 Toxicological Evaluation of New Drugs
P. MILLER, Roussel Laboratories Ltd, Swindon, UK

4.8 Clinical Pharmacology and Clinical Trials
J. A. SUTTON, Knoll Ltd, Maidenhead, UK

4.9 Post-marketing Surveillance
N. S. B. RAWSON, Drug Safety Research Unit, Southampton, UK

4.10 Animal Experimentation
J. H. SEAMER and L. A. BROWN, Salisbury, UK

4.11 Orphan Drugs
B. SPILKER, Burroughs Wellcome Co., Research Triangle Park, NC, USA

4.12 Patents
J.-C. VIEILLEFOSSE, Roussel-Uclaf, Romainville, France

4.13 Trade Marks
E. A. HORAK, Ciba-Geigy Ltd, Basle, Switzerland

4.14 Sources of Information
S. A. NORTH and S. E. WARD, Glaxo Group Research Ltd, Ware, UK,
J. SKIDMORE, Smith Kline & French Research Ltd, Welwyn, UK and
I. J. TARR, PJB Publications, Richmond, UK

Subject Index